---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-001948"
form_type: "8-K"
ticker: "CRVS"
cik: "0001626971"
company_name: "Corvus Pharmaceuticals, Inc."
filed_at: "2023-03-28T23:59:59+00:00"
generated_at: "2026-06-17T12:52:41.593883+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Corvus reports Q4 net loss of $9.8M; identifies predictive biomarker for CPI-818 in T-cell lymphoma

## Summary
- Cash $42.3M at Dec 31, 2022 (from $69.5M); 2023 operating burn guided $19-22M with year-end cash $20-23M.
- Q4 2022 net loss $9.8M vs $9.2M year ago; R&D expense $4.1M.
- CPI-818 Phase 1/1b: ALC >900 biomarker identified; 4/8 biomarker-positive patients had objective responses.
- Median PFS 28.1 months in ALC>900 patients vs 2.1 months in ALC<900 patients (n=13 evaluable).
- Atopic dermatitis trial delayed to conserve cash; FDA meeting for Phase 3 lymphoma trial planned for 2023.

## SEC filing metadata
- accession: 0001171843-23-001948
- form_type: 8-K
- ticker: CRVS
- cik: 0001626971
- company_name: Corvus Pharmaceuticals, Inc.
- filed_at: 2023-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626971/000117184323001948/0001171843-23-001948-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626971/000117184323001948/f8k_032823.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-001948
- JSON: https://secwatch.observer/filing/0001171843-23-001948.json
- Plain text: https://secwatch.observer/filing/0001171843-23-001948.txt

## Key facts
- Earnings Releases
  Corvus Pharmaceuticals, Inc. reported financial results for the fourth quarter and year ended December 31, 2022.
  - Period: the fourth quarter and year ended December 31, 2022
  - Result: reported results
  source text: On March 28, 2023, Corvus Pharmaceuticals, Inc. issued a press release regarding, among other matters, its financial results for the fourth quarter and full year ended December 31, 2022 and its financial position as of December 31, 2022, and provided a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1626971/000117184323001948/0001171843-23-001948-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.